Ertugliflozin: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: February 11, 2026🚩 Report this page

Ertugliflozin

Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors

Sold as Steglatro · Steglujan · Segluromet

EU EMA

Drug class: Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
Availability: See label
Markets covered: 1
Products on record: 3

A10BKSodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors

Overview

Ertugliflozin is an active pharmaceutical ingredient in the Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors group (A10BK). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
EU European Union	EMA	3	February 11, 2026

EUEuropean Union· EMA

3 products

Uses

EUOfficial regulatory label· revised February 11, 2026[1]

Steglatro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• in addition to other medicinal products for the treatment of diabetes. 1. 3

How to take

Drug interactions

Known interactions involving Ertugliflozin. Select one for details. This list is informational and not a complete interaction checker.

Gatifloxacin Acebutolol Acetazolamide Acetohexamide Albuterol Alfuzosin Aliskiren Alpelisib Alprostadil Ambrisentan Amiloride Amlodipine Amprenavir Amyl Nitrite Aripiprazole Asenapine Asparaginase Atazanavir Atenolol Avanafil Azilsartan Benazepril Bendroflumethiazide Benzphetamine Benzthiazide Bepridil Betamethasone Betaxolol Bisoprolol Bortezomib Bosentan Brentuximab Vedotin Brexpiprazole Brigatinib Bumetanide Calaspargase Pegol Captopril Cariprazine Carteolol Carvedilol Ceritinib Chlorothiazide Chlorpromazine Chlorpropamide Chlorthalidone Chromic Chloride Chromium Picolinate Cinoxacin Ciprofloxacin Clarithromycin Clevidipine Clonidine Clozapine Copanlisib Corticotropin Cosyntropin Cyclandelate Danazol Darunavir Deflazacort Delafloxacin Deserpidine Desogestrel Dexamethasone Dexfenfluramine Diazoxide Dienestrol Diethylpropion Diethylstilbestrol Diltiazem Dobutamine Dopamine Doxazosin Drospirenone Enalapril Enoxacin Ephedrine Epinephrine Eplerenone Epoprostenol Eprosartan Esmolol Estradiol Estramustine Estrone Ethacrynate Ethanol Ethinyl Estradiol Etonogestrel Everolimus Felodipine Fenfluramine Fenoldopam Fludrocortisone Fluphenazine Formoterol Fosamprenavir Fosinopril Fosphenytoin Furosemide Gemifloxacin Glimepiride Glipizide Glyburide Goserelin Grepafloxacin Guanabenz Guanadrel Guanethidine Guanfacine Histrelin Hydralazine Hydrochlorothiazide Hydrocortisone Hydroflumethiazide Iloperidone Iloprost Indacaterol Indapamide Indinavir Insulin Degludec Insulin Detemir Insulin Glargine Insulin Lispro Irbesartan Isoniazid Isoproterenol Isosorbide Dinitrate Isoxsuprine Isradipine Labetalol Lanreotide Leuprolide Levamlodipine Levofloxacin Levonorgestrel Levothyroxine Liothyronine Lisinopril Lithium Carbonate Lofexidine Lomefloxacin Lorcaserin Losartan Lumateperone Lurasidone Mannitol Mazindol Mecamylamine Medroxyprogesterone Mephentermine Mesoridazine Metaproterenol Metaraminol Methazolamide Methdilazine Methotrimeprazine Methoxamine Methyldopa Methylprednisolone Metolazone Metoprolol Metyrosine Midostaurin Minoxidil Moexipril Moxifloxacin Nadolol Nateglinide Nebivolol Nelfinavir Nesiritide Niacin Nicardipine Nifedipine Nimodipine Nisoldipine Nitroglycerin Nitroprusside Norepinephrine Norethindrone Norfloxacin Norgestrel Octreotide Ofloxacin Olanzapine Olmesartan Olodaterol Omacetaxine Mepesuccinate Orlistat Paliperidone Papaverine Pasireotide Pegaspargase Pegvisomant Penbutolol Pentamidine Perindopril Perphenazine Phendimetrazine Phenoxybenzamine Phentermine Phentolamine Phenylephrine Phenylpropanolamine Phenytoin Pindolol Polythiazide Prazosin Prednisolone Prednisone Prochlorperazine Progesterone Promazine Promethazine Propiomazine Propranolol Pseudoephedrine Quetiapine Quinapril Quinestrol Ramipril Ranolazine Repaglinide Reserpine Riociguat Risperidone Ritodrine Ritonavir Salmeterol Saquinavir Selexipag Sermorelin Sibutramine Sildenafil Silodosin Sirolimus Somapacitan Somatrem Somatropin

Showing 240 of 293. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]European Medicines Agency · EMEA/H/C/004315 · revised February 11, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

EUOfficial regulatory label· Adverse reactions· revised February 11, 2026[1]

Summary of the safety profile The safety and tolerability of ertugliflozin were assessed in 7 placebo- or active comparator-controlled studies with a total of 3 409 patients with type 2 diabetes mellitus treated with ertugliflozin 5 mg or 15 mg.
9 years. Pool of placebo-controlled trials evaluating Steglatro 5 mg and 15 mg The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials. 1). These data reflect exposure of 1 029 patients to ertugliflozin with a mean exposure duration of approximately 25 weeks.
Patients received ertugliflozin 5 mg (N=519), ertugliflozin 15 mg (N=510), or placebo (N=515) once daily. The most commonly reported adverse reactions across the clinical program were urinary tract infections, vulvovaginal mycotic infection and other female genital mycotic infections.
4). Tabulated list of adverse reactions Adverse reactions listed below are classified according to frequency and system organ class (SOC), within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Frequency categories are defined according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), not known (cannot be estimated from the available data).
4. † See subsections below for additional information. ‡ Includes: pollakiuria, micturition urgency, polyuria, urine output increased, and nocturia. § Includes: thirst and polydipsia. 9%. 5%. 6%). 1%). a Adverse reactions were identified through post-marketing surveillance.
10 Description of selected adverse reactions Volume depletion Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion. In the pool of placebo-controlled studies, the incidence of adverse events related to volume depletion (dehydration, dizziness postural, presyncope, syncope, hypotension, and orthostatic hypotension) was low (< 2%) and not notably different across the ertugliflozin and placebo groups.
4). 7%, and 0% respectively. 9%). 4% in each group. 7% in the placebo group. 3% in the placebo group. 2% for ertugliflozin 5 mg and 15 mg, respectively). In the VERTIS CV sub-studies, when ertugliflozin was added to insulin with or without metformin, the […]

EUOfficial regulatory label· Warnings and precautions· revised February 11, 2026[1]

General Steglatro should not be used in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis (DKA) in these patients. Hypotension/Volume depletion Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction.
73 m2 or CrCl less than 60 mL/min), elderly patients (≥ 65 years), patients on diuretics, or patients on anti-hypertensive therapy with a history of hypotension. Before initiating Steglatro, volume status should be assessed and corrected if indicated.
Monitor for signs and symptoms after initiating therapy. Due to its mechanism of action, ertugliflozin induces an osmotic diuresis and increases serum creatinine and decreases eGFR. 8). , physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving ertugliflozin.
Temporary interruption of treatment with ertugliflozin should be considered until the fluid loss is corrected. Diabetic ketoacidosis Rare cases of DKA, including life-threatening and fatal cases, have been reported in clinical trials and post-marketing in patients treated with sodium glucose co-transporter-2 (SGLT2) inhibitors, including ertugliflozin.
In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/L (250 mg/dL). It is not known if DKA is more likely to occur with higher doses of ertugliflozin.
The risk of DKA must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.
In patients where DKA is suspected or diagnosed, treatment with ertugliflozin should be discontinued immediately. Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses.
Monitoring of ketones is recommended in these patients. Measurement of blood ketone levels is preferred to urine. Treatment with ertugliflozin may be restarted when the ketone values are normal and the patient’s condition has stabilised.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

EUEuropean Union· EMA

Drug interactions

Drugs in the same class

Sources & citations